Your session is about to expire
← Back to Search
Behavioral Intervention
DTTC Frequency for Childhood Apraxia of Speech
N/A
Recruiting
Led By Jenya Iuzzini-Seigel, PhD
Research Sponsored by Marquette University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
2;6-7;11 years of age at treatment commencement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre to post-treatment follow-up (6-12 weeks of treatment plus 12 weeks post completion of treatment)
Awards & highlights
Study Summary
This trial will compare how children with CAS respond to different treatment frequencies to figure out the optimal treatment schedule.
Who is the study for?
This trial is for children aged between 2 years and 6 months to 7 years and 11 months with a confirmed diagnosis of Childhood Apraxia of Speech (CAS). They must speak English primarily, have no severe developmental disorders, uncorrected vision or hearing loss, significant speech treatment from other sources during the study, or cognitive scores below certain thresholds.Check my eligibility
What is being tested?
The trial tests how often kids with CAS should get Dynamic Temporal and Tactile Cueing (DTTC) treatment. It compares two groups: one gets DTTC twice a week for 12 weeks; the other four times a week for six weeks. The focus is on whether more frequent sessions improve word accuracy in speech.See study design
What are the potential side effects?
Since DTTC is a non-invasive speech therapy technique focusing on cues to help children learn correct speech movements, it does not involve medication or procedures that typically cause physical side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 2 and 11 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pre to post-treatment follow-up (6-12 weeks of treatment plus 12 weeks post completion of treatment)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre to post-treatment follow-up (6-12 weeks of treatment plus 12 weeks post completion of treatment)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes to whole word accuracy
Secondary outcome measures
Functional communication
Phoneme accuracy
Speech Intelligibility
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: High Dose FrequencyExperimental Treatment1 Intervention
This group will receive treatment 4x/week for 6 weeks
Group II: Low Dose FrequencyActive Control1 Intervention
This group will receive treatment 2x/week for 12 weeks
Find a Location
Who is running the clinical trial?
New York UniversityOTHER
226 Previous Clinical Trials
314,057 Total Patients Enrolled
2 Trials studying Childhood Apraxia of Speech
112 Patients Enrolled for Childhood Apraxia of Speech
Remarkable Speech and MovementUNKNOWN
Marquette UniversityLead Sponsor
62 Previous Clinical Trials
200,263 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have vision problems that glasses or contacts can't fix.Your score on a specific test for thinking and problem solving is lower than 70.I have hearing loss.You have certain abnormalities in the roof of your mouth or in the structure of your face.You have other conditions that affect how you learn or develop, like autism or intellectual disability.You don't show signs of trying to communicate, pay attention to the doctor's face, or copy what the doctor does during the DEMSS.I am between 2 and 11 years old.My child scored below 70 in a language test appropriate for their age.I have been diagnosed with severe speech difficulties.The research team has confirmed that you have CAS based on specific criteria described in certain research studies.I am not receiving speech therapy elsewhere during this study but may be getting language or communication support.
Research Study Groups:
This trial has the following groups:- Group 1: Low Dose Frequency
- Group 2: High Dose Frequency
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
To which population is this clinical trial open?
"To be considered for this trial, 30 to 95 month old patients must demonstrate childhood apraxia of speech. 60 participants are needed in order to complete the study."
Answered by AI
How many participants are being treated under this investigation?
"Affirmative. Clinicaltrials.gov serves as a testament to this trial's active recruitment status, which started on March 1st 2023 and was recently updated on July 25th 2023. 60 patients are needed for the single medical site that is taking part in this research study."
Answered by AI
Does this trial encompass individuals aged 18 or above?
"To qualify for this medicinal experiment, applicants must be between 30 months and 95 years of age. Additionally, there are 6 trials available to those under 18 while 7 studies exist for people that exceed the age of 65."
Answered by AI
Are there opportunities to join this trial at the present moment?
"Affirmative. According to the data from clinicaltrials.gov, this medical study, which was first shared on March 1st 2023 is still recruiting patients. 60 individuals are required for this experiment and it will be conducted at a single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger